PMID- 36451919
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221202
IS  - 2297-055X (Print)
IS  - 2297-055X (Electronic)
IS  - 2297-055X (Linking)
VI  - 9
DP  - 2022
TI  - Risk of hypovolemia associated with sodium-glucose cotransporter-2 inhibitors 
      treatment: A meta-analysis of randomized controlled trials.
PG  - 973129
LID - 10.3389/fcvm.2022.973129 [doi]
LID - 973129
AB  - AIM OF THE REVIEW: To assess the risk of hypovolemia for sodium-glucose 
      cotransporter-2 (SGLT2) inhibitors treatment. METHOD: A systematic literature 
      retrieval was performed in PubMed, Embase, Cochrane Central Register of 
      Controlled Trials (CENTRAL), Web of Science, and Scopus from inception up to 4 
      October 2022, Data for study characteristics and outcomes of interest were 
      extracted from each eligible study. Risk ratios (RRs) with a 95% confidence 
      interval (CI) for hypovolemia were calculated using a random-effect model. 
      RESULTS: A total of 57 studies (n = 68,622) were included in our meta-analysis, 
      with a result of 1,972 hypovolemia incidents (1,142 in the SGLT2 inhibitors group 
      and 830 in the control group). The pooled RR was 1.12 (95% CI: 1.02-1.22). It is 
      evident that receiving SGLT2 inhibitors increased the risk of hypovolemia. When 
      stratified by category of SGLT2 inhibitors the result was consistent; when the 
      subgroup was analyzed by age, the pooled RR was 1.07 (95% CI: 0.94-1.23) in 
      patients aged >/=65 years and 1.14 (95% CI: 1.02-1.28) in those aged <65 years. 
      When comparing the baseline estimated glomerular filtration rate (eGFR) of less 
      than or equal to 60 mL/min/1.73 m(2) with a baseline eGFR greater than 60 
      mL/min/1.73 m(2), the pooled RR was 1.21, (95% CI: 1.00-1.46) and 1.08, (95%CI: 
      0.98-1.20), respectively. CONCLUSION: Our meta-analysis has demonstrated that 
      SGLT2 inhibitors increased the risk of hypovolemia in patients with Type 2 
      Diabetes Mellitus (T2DM). It is necessary to pay attention to the risk of 
      hypovolemia associated with SGLT2 inhibitors, especially in older individuals and 
      those with moderate renal impairment. SYSTEMATIC REVIEW REGISTRATION: 
      [https://www.crd.york.ac.uk/prospero/], identifier [CRD42020156254].
CI  - Copyright (c) 2022 Rong, Zhu, Wen, Liu, Li, Gou and Chen.
FAU - Rong, Xi
AU  - Rong X
AD  - Department of Cardiology, The Affiliated Hospital of Southwest Medical 
      University, Southwest Medical University, Luzhou, China.
FAU - Zhu, Yawen
AU  - Zhu Y
AD  - Department of General Practice, West China Hospital, Sichuan University, Chengdu, 
      China.
FAU - Wen, Bo
AU  - Wen B
AD  - dMed Biopharmaceutical Company Limited, Shanghai, China.
FAU - Liu, Kai
AU  - Liu K
AD  - Department of Cardiology, West China Hospital, Sichuan University, Chengdu, 
      China.
FAU - Li, Xinran
AU  - Li X
AD  - Department of Cardiology, West China Hospital, Sichuan University, Chengdu, 
      China.
FAU - Gou, Qiling
AU  - Gou Q
AD  - Department of Cardiology, West China Hospital, Sichuan University, Chengdu, 
      China.
FAU - Chen, Xiaoping
AU  - Chen X
AD  - Department of Cardiology, West China Hospital, Sichuan University, Chengdu, 
      China.
LA  - eng
PT  - Systematic Review
DEP - 20221114
PL  - Switzerland
TA  - Front Cardiovasc Med
JT  - Frontiers in cardiovascular medicine
JID - 101653388
PMC - PMC9701837
OTO - NOTNLM
OT  - RCTs
OT  - adverse event (AE)
OT  - hypovolemia
OT  - meta-analysis
OT  - sodium-glucose cotransporter-2 inhibitors
OT  - volume depletion
COIS- Author BW was employed by dMed Biopharmaceutical Company Limited. The remaining 
      authors declare that the research was conducted in the absence of any commercial 
      or financial relationships that could be construed as a potential conflict of 
      interest.
EDAT- 2022/12/02 06:00
MHDA- 2022/12/02 06:01
PMCR- 2022/01/01
CRDT- 2022/12/01 02:32
PHST- 2022/06/19 00:00 [received]
PHST- 2022/10/26 00:00 [accepted]
PHST- 2022/12/01 02:32 [entrez]
PHST- 2022/12/02 06:00 [pubmed]
PHST- 2022/12/02 06:01 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fcvm.2022.973129 [doi]
PST - epublish
SO  - Front Cardiovasc Med. 2022 Nov 14;9:973129. doi: 10.3389/fcvm.2022.973129. 
      eCollection 2022.